Analysts await Akebia Therapeutics, Inc. (NASDAQ:AKBA) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $-0.46 EPS, up 13.04% or $0.06 from last year’s $-0.52 per share.

At the moment 7 analysts are watching Akebia Therapeutics, Inc. (NASDAQ:AKBA), 2 rate it “Buy”, 4 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 4 analysts have a mean sales target of 1.88 million. For the quarter ending Jun-16, 4 analysts have a mean sales target of 21.88 million whilst for the year ending Dec-16, 7 analysts have a mean target of 45.76 million.

In terms of earnings per share, 3 analysts have a -0.76 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 3 analysts have a -0.84 EPS mean target and for the quarter ending Jun-16 there are 6 estimates of -2.07 EPS.

The biggest institutional shareholders in Akebia Therapeutics, Inc. include Eagle Asset Management Inc which owns 4 million shares in the company valued at $42.42 million. Fidelity Management and Research Company is the second biggest holder with 2 million shares currently valued at 25.40 million whilst BlackRock Advisors LLC has 2 million shares valued at 21.88 million.

Total shares held by institutions as of the most recent company filings are 19,877,657 with a reported 2,671,303 bought and 693,280 sold. These holdings make up 70.48% of the company’s outstanding shares.

Currently insiders hold 797,395 shares in the business which makes up 2.60% of shares. The biggest holder currently is Mr. John P. Butler who owns 351,173 shares (1.15% of those outstanding), whilst Mr. Robert Shalwitz holds 247,540 (0.81% of shares outstanding) and Nicole R. Hadas holds 87,084 (0.28% of shares outstanding).

The stock increased 4.97% or $0.41 during the last trading session, hitting $8.99. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has fallen 17.46% over the past 6 months and is downtrending.